NewAmsterdam Pharma Reports Promising Phase 3 Trial Results

The latest update is out from NewAmsterdam Pharma Company ( (NAMS) ).

NewAmsterdam Pharma has announced promising results from its Phase 3 TANDEM clinical trial, showcasing the effectiveness of a fixed-dose combination of obicetrapib and ezetimibe in significantly reducing LDL-C levels in patients with cardiovascular disease or high-risk factors. The trial met its primary endpoints, demonstrating a 50% reduction in LDL-C compared to placebo, and showed that over 70% of patients achieved LDL-C levels below 55 mg/dL. The combination treatment was well tolerated, aligning with past safety data, and is expected to support global regulatory filings.

For detailed information about NAMS stock, go to TipRanks’ Stock Analysis page.